Upadacitinib for treating giant cell arteritis [ID6299]
In development
Reference number: GID-TA11330
Expected publication date: TBC
The company, AbbVie, has asked to submit more evidence as part of the draft guidance response and requires more time to do this.
Therefore, the committee meeting discussion on 4 March 2026 will be rearranged to a later date. The website will be updated with the new committee meeting date once it is known.